Skip to content

US · NVNO · MEDICAL - DEVICES

enVVeno Medical Corporation (NVNO) intrinsic value and stock valuation

$5.25as of 2026-11-21 · Mkt cap 182.69K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

enVVeno Medical Corporation DCF and intrinsic value

InvestorsCraft values NVNO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NVNO’s statements →

enVVeno Medical Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Irvine, CA 92618 envveno.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-19.47M
20142025
Free cash flow
-$-15.57M
20142025
Total equity
$27.1M+30.7% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-20.9M-$-23.83M-$-25.24M-$-24.93M-$-16.89M
Net income-$-19.47M-$-21.82M-$-23.52M-$-24.67M-$-16.53M
EPSd-$-33M-$-2.18B-$-2.35B-$-2.47B-$-1.65B
Operating cash flow-$-15.57M-$-16.84M-$-18.86M-$-15.62M-$-11.85M
Capital expenditure-$-10K-$-40K-$-30K-$-120K-$-370K
Free cash flow-$-15.57M-$-16.88M-$-18.89M-$-15.73M-$-12.22M
Total assets$29.6M$45M$48.6M$41.7M$57.7M
Total debt$700K$1.06M$1.4M$1.72M$2.01M
Net debt-$-2.37M-$-690K-$-2.22M-$-2.84M-$-52.72M
Total equity$27.1M$42.2M$46.2M$38.7M$54.4M
Cash and short-term investments$28.2M$43.2M$46.4M$39M$54.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$530K$550K$530K$450K
Gross profit$0.00-$-530K-$-550K-$-530K-$-450K
Research and development expenses$9.98M$12.3M$13.6M$9.91M$5.73M
Selling, general and administrative expenses$10.9M$11.1M$11.1M$14.5M$10.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$20.9M$23.3M$24.7M$24.4M$16.4M
Cost and expenses$20.9M$23.8M$25.2M$24.9M$16.9M
Interest income$690K$390K$180K$160K$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$490K$530K$550K$530K$450K
Ebitda-$-18.98M-$-21.29M-$-22.97M-$-24.14M-$-16.07M
Operating income-$-20.9M-$-23.83M-$-25.24M-$-24.93M-$-16.89M
Total other income/expenses, net$1.43M$2.01M$1.72M$260K$360K
Income before tax-$-19.47M-$-21.82M-$-23.52M-$-24.67M-$-16.53M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-19.47M-$-21.82M-$-23.52M-$-24.67M-$-16.53M
Weighted average shares outstanding$590K$490K$350K$320K$250K
Weighted average diluted shares outstanding$590K$10K$10K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$28.2M$43.2M$46.4M$39M$54.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$28.8M$43.7M$46.9M$39.4M$55M
Property, plant and equipment, net$700K$1.19M$1.68M$2.19M$2.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$740K$1.22M$1.71M$2.23M$2.66M
Total assets$29.6M$45M$48.6M$41.7M$57.7M
Accounts payable$360K$1.01M$430K$650K$560K
Short-term debt$390K$360K$340K$310K$290K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.12M$2.1M$1.37M$1.53M$1.58M
Long-term debt$310K$700K$1.06M$1.4M$1.71M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$310K$700K$1.06M$1.4M$1.71M
Capital lease obligations$700K$700K$1.4M$1.72M$2.01M
Total liabilities$2.43M$2.79M$2.44M$2.93M$3.29M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-171.33M-$-151.85M-$-130.04M-$-106.52M-$-81.85M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$27.1M$42.2M$46.2M$38.7M$54.4M
Total investments$25.2M$41.4M$42.8M$34.5M$0.00
Total debt$700K$1.06M$1.4M$1.72M$2.01M
Net debt-$-2.37M-$-690K-$-2.22M-$-2.84M-$-52.72M
Cash flow statement
20252024202320222021
Net income-$-19.47M-$-21.82M-$-23.52M-$-24.67M-$-16.53M
Depreciation and amortization$490K$530K$550K$530K$450K
Stock-based compensation$3.42M$4.14M$5.2M$8.99M$6M
Change in working capital-$-400K$290K-$-620K-$-420K-$-1.15M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00-$-220K$90K-$-830K
Net cash provided by operating activities-$-15.57M-$-16.84M-$-18.86M-$-15.62M-$-11.85M
Investments in property, plant and equipment-$-10K-$-40K-$-30K-$-120K-$-370K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$15.9M$1.33M-$-7.87M-$-34.55M-$-370K
Common stock issued$1.02M$13.6M$25.8M$0.00$57.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.02M$13.6M$25.8M$0.00$57.6M
Net change in cash$1.31M-$-1.87M-$-940K-$-50.17M$45.4M
Cash at end of period$3.06M$1.75M$3.62M$4.55M$54.7M
Operating cash flow-$-15.57M-$-16.84M-$-18.86M-$-15.62M-$-11.85M
Capital expenditure-$-10K-$-40K-$-30K-$-120K-$-370K
Free cash flow-$-15.57M-$-16.88M-$-18.89M-$-15.73M-$-12.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About enVVeno Medical Corporation

        enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

        CEO
        Robert A. Berman
        Employees
        33
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of enVVeno Medical Corporation (NVNO)?

        InvestorsCraft does not currently publish an intrinsic value for NVNO. How the IC value is calculated.

        Is NVNO undervalued?

        InvestorsCraft does not publish an undervaluation signal for NVNO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.